Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Hsp 70

Abstract (Set) Ovarian cancer is responsible for the highest mortality rate among patients with gynecologic malignancies. Therefore, there is an emerging need for innovative therapies for the control of advanced ovarian cancer. Immunotherapy has emerged as a potentially plausible approach for the control of ovarian cancer. JHU scientists have generated heat shock protein 70 (Hsp70) secreting murine ovarian cancer cells that express luciferase (MOSEC-Iuc). They also characterized the antigen-specific immune response and the anti-tumor effect of the MOSEC-luc cells expressing Hsp70 using non-invasive luminescence images to measure the amount of ovarian tumors in the peritoneal cavity of mice. Scientists found that mice challenged with MOSEC-luc cells expressing Hsp70 generate significant antigen-specific CD8+ T cell immune response. Furthermore, it was also found that mice vaccinated with irradiated MOSEC-luc cells expressing Hsp70 generate significant therapeutic effect against MOSEC-luc cells. Description (Set) Proposed Use (Set) The employment of Hsp70-secreting ovarian tumor cells represents a potentially effective therapy to control lethal ovarian cancer. DNA vaccine can be produced with this invention.

Inventor(s): Hung, Chien-Fu ,Wu, T.C.

Type of Offer: Licensing



« More Medical Patents

---